MA38828A1 - Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations - Google Patents

Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations

Info

Publication number
MA38828A1
MA38828A1 MA38828A MA38828A MA38828A1 MA 38828 A1 MA38828 A1 MA 38828A1 MA 38828 A MA38828 A MA 38828A MA 38828 A MA38828 A MA 38828A MA 38828 A1 MA38828 A1 MA 38828A1
Authority
MA
Morocco
Prior art keywords
antibodies
pai
plasminogen activator
activator inhibitor
inhibitor type
Prior art date
Application number
MA38828A
Other languages
English (en)
Inventor
Dorothea KOMINOS
Alla Pritsker
Nicolas Baurin
Han Li
Alexey Rak
Patrick Grailhe
Magali Mathieu
Christopher Ryan Morgan
Cyril Daveu
Francis Duffieux
Philip Janiak
Bruno Poirier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA38828A1 publication Critical patent/MA38828A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps qui se lient de façon spécifique à l'inhibiteur des activateurs du plasminogène de type 1 (pai-1). L'invention concerne également des compositions pharmaceutiques, ainsi que des acides nucléiques codant pour des anticorps anti-pai-1, des vecteurs d'expression recombinés et des cellules hôtes utilisables en vue de la production desdits anticorps, ou de fragments de ceux-ci. L'invention concerne également des procédés d'utilisation d'anticorps permettant de moduler l'activité de pai-1 ou de détecter pai-1, soit
MA38828A 2014-05-22 2014-08-13 Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations MA38828A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305757 2014-05-22
PCT/US2014/050896 WO2015023752A1 (fr) 2013-08-13 2014-08-13 Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations

Publications (1)

Publication Number Publication Date
MA38828A1 true MA38828A1 (fr) 2018-01-31

Family

ID=50846892

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38828A MA38828A1 (fr) 2014-05-22 2014-08-13 Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MA44593A MA44593B1 (fr) 2014-05-22 2014-08-13 Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA44593A MA44593B1 (fr) 2014-05-22 2014-08-13 Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations

Country Status (10)

Country Link
EP (2) EP3620472A1 (fr)
AU (1) AU2014306649A1 (fr)
CA (1) CA2920890A1 (fr)
EA (1) EA201991409A3 (fr)
IL (1) IL244018A0 (fr)
MA (2) MA38828A1 (fr)
SG (1) SG11201600928SA (fr)
TW (3) TW201722994A (fr)
UY (1) UY35703A (fr)
WO (1) WO2015023752A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101916959B1 (ko) * 2015-07-13 2018-11-08 김동구 정자의 성 감별용 항체 및 이의 용도
WO2017010796A1 (fr) * 2015-07-13 2017-01-19 김동구 Anticorps de détermination du sexe du sperme, et son utilisation
JP7525980B2 (ja) 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
EP3395353B1 (fr) 2015-12-18 2024-03-06 Talengen International Limited Plasminogène pour le prévention ou le traitement de la neuropathie diabétique
ES2961967T3 (es) 2015-12-18 2024-03-14 Talengen Int Ltd Plasminógeno para su uso en el tratamiento de la angiocardiopatía diabética
CN106890323A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗肝组织损伤及其相关病症的方法
WO2017101873A1 (fr) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 Méthode de prévention ou de traitement des radiolésions et des lésions chimiques
WO2017101868A1 (fr) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 Procédé pour empêcher et traiter une néphropathie diabétique
TWI624267B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
CA3047181A1 (fr) 2016-12-15 2018-06-21 Talengen International Limited Methode et medicament pour la prevention et le traitement de l'obesite
CA3047174A1 (fr) 2016-12-15 2018-06-21 Talengen International Limited Methode de prevention et de traitement d'une fibrose hepatique
WO2018107684A1 (fr) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 Méthode de traitement et de prévention de l'athérosclérose et de ses complications
CN108210899A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗组织器官纤维化的药物及其用途
EP3643321A4 (fr) 2017-06-19 2021-05-05 Talengen International Limited Procédé de régulation et contrôle de glp-1/glp-1r et médicament associé

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2341029A1 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
EP1006183A1 (fr) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002216847A1 (en) 2000-10-26 2002-05-06 K.U. Leuven Research And Development Epitopes of pai-1
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
WO2002060919A2 (fr) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules a demi-vies longues, compositions et utilisations de celles-ci
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004016750A2 (fr) 2002-08-14 2004-02-26 Macrogenics, Inc. Anticorps specifiques du recepteur fc$g(g)riib et procedes d'utilisation de ces anticorps
CA2499816C (fr) 2002-09-27 2013-07-30 Xencor, Inc. Variants fc optimises et methodes destinees a leur generation
CA2502904C (fr) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese
EP2368578A1 (fr) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
CZ294996B6 (cs) 2003-07-16 2005-04-13 Ústav Makromolekulární Chemie Av Čr Reaktivní polymery a kopolymery na bázi N-(2-hydroxypropyl)methakrylamidu, způsob jejich přípravy a jejich použití pro syntézu polymerních léčiv, pro modifikaci biologicky aktivních proteinů a přípravu systémů pro dopravu genů
CA2536408A1 (fr) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
JP2008504002A (ja) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
PT1706424E (pt) 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
CN101014619B (zh) 2004-07-15 2010-11-03 赞科股份有限公司 优化的Fc变体
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
CN101061984B (zh) 2006-04-29 2012-02-08 香港理工大学 利用肌电信号提供机械帮助的康复机器人系统
BRPI0815983A2 (pt) 2007-08-29 2018-05-22 Sanofi Aventis anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2198055A4 (fr) 2007-09-07 2012-04-18 Cisthera Inc Anticorps pai-1 humanisés
EP2566890A4 (fr) * 2010-05-03 2013-11-20 Abbvie Inc Anticorps anti-pai-1 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP3033359B1 (fr) 2019-11-06
TW201722994A (zh) 2017-07-01
TWI592426B (zh) 2017-07-21
TW201520229A (zh) 2015-06-01
AU2014306649A1 (en) 2016-03-17
EA201991409A3 (ru) 2020-01-31
CA2920890A1 (fr) 2015-02-19
WO2015023752A1 (fr) 2015-02-19
SG11201600928SA (en) 2016-03-30
IL244018A0 (en) 2016-04-21
MA44593A1 (fr) 2019-12-31
TW201734054A (zh) 2017-10-01
EP3620472A1 (fr) 2020-03-11
EA201991409A2 (ru) 2019-11-29
UY35703A (es) 2015-03-27
EP3033359A1 (fr) 2016-06-22
MA44593B1 (fr) 2020-06-30

Similar Documents

Publication Publication Date Title
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201792047A1 (ru) Новые соединения
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
NZ743008A (en) Compositions and methods for internalizing enzymes
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
MY187265A (en) Bicyclic heterocycles as fgfr4 inhibitors
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
UA112416C2 (uk) Антитіло до fap і способи його застосування
MX2019001011A (es) Compuestos farmaceuticos.
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
EA202091711A1 (ru) ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ
MX2024009001A (es) Inhibidores de la pcsk9 y metodos de uso de los mismos.
WO2018119425A3 (fr) Anticorps anti-lilrb3 et leurs procédés d'utilisation
EA201792608A3 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
EA201491471A1 (ru) Состав, содержащий антитело против ил-17
MA45831B1 (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его